Korean J Hematol.  2012 Jun;47(2):119-125. 10.5045/kjh.2012.47.2.119.

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma

• Jo JC
• Yoon DH
• Kim S
• Park JS
• Park CS
• Huh J
• Lee SW
• Ryu JS
• Suh C

• KMID: 2083605
• DOI: http://doi.org/10.5045/kjh.2012.47.2.119

Abstract

BACKGROUND
Radioimmunotherapy agents have a highly significant role in autologous stem cell transplantation as they improve tolerability and increase the efficacy of the conditioning regimen.
METHODS
We retrospectively analyzed the efficacy and toxicity of yttrium-90 ibritumomab tiuxetan (Zevalin) combined with intravenous busulfan, cyclophosphamide, and etoposide (Z-BuCyE) compared with those of BuCyE alone followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The efficacy, toxicity, and engraftment characteristics were compared between 19 patients who received Z-BuCyE and 19 historical controls who received BuCyE.
RESULTS
The 2 treatment groups shared similar baseline characteristics. The median time to platelet engraftment (>20x10(9)/L) and neutrophil engraftment (>0.5x10(9)/L) did not significantly differ between the Z-BuCyE group (12 days and 10 days, respectively) and the BuCyE group (12 days and 10 days, respectively). No significant differences were observed between the groups with respect to toxicities and treatment-related mortality. The median follow-up period was 30.4 months, and median event-free survival was generally better in the Z-BuCyE group (12.5 months) vs. the BuCyE group (6.2 months, P=0.236). No significant difference in overall survival between the groups was noted.
CONCLUSION
Adding ibritumomab tiuxetan to BuCyE high-dose chemotherapy may benefit patients with relapsed or refractory B-cell NHL with no risk of additional toxicity.

Keyword

Yttrium-90 ibritumomab tiuxetan; BuCyE; Autologous stem cell transplantation; Non-Hodgkin lymphoma

MeSH Terms

Antibodies, Monoclonal
B-Lymphocytes
Blood Platelets
Busulfan
Cyclophosphamide
Disease-Free Survival
Etoposide
Follow-Up Studies
Humans
Lymphoma, Non-Hodgkin
Neutrophils
Radioimmunotherapy
Retrospective Studies
Stem Cell Transplantation
Antibodies, Monoclonal
Busulfan
Cyclophosphamide
Etoposide

Figure

• 

  Fig. 1 Event-free survival (EFS, A), duration of complete response (CR, B), and overall survival (OS, C) after high-dose chemotherapy (HDC) with Z-BuCyE or BuCyE followed by autologous stem cell transplantation (ASCT).

Reference

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995. 333:1540–1545.

2. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003. 21:3918–3927.

3. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005. 105:2677–2684.

4. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood. 2000. 96:2399–2404.

5. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001. 19:406–413.

6. Josting A, Sieniawski M, Glossmann JP, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005. 16:1359–1365.

7. Gianni AM, Berinstein NL, Evans PA, López-Guillermo A, Solano C. Stem-cell transplantation in non-Hodgkin's lymphoma: improving outcome. Anticancer Drugs. 2002. 13:Suppl 2. S35–S42.

8. Gisselbrecht C, Bethge W, Duarte RF, et al. Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007. 40:1007–1017.

9. Shimoni A, Zwas ST, Oksman Y, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol. 2007. 35:534–540.

10. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008. 26:90–95.

11. Khouri IF, Saliba RM, Hosing C, et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). Blood. 2006. 108:Abst 315.

12. Krishnan AY, Nademanee A, Raubitschek A, et al. A comparison of Beam and yttrium 90 ibritumomab tiuxetan (Zevalin(R)) in addition to Beam (Z-BEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas: Impact of radioimmunotherapy on transplant outcomes. Blood. 2006. 108:Abst 3043.

13. Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012. [Epub ahead of print].

14. Copelan EA, Penza SL, Pohlman B, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000. 25:1243–1248.

15. Hänel M, Kröger N, Sonnenberg S, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002. 81:96–102.

16. Kim JG, Sohn SK, Chae YS, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007. 40:919–924.

17. Kim JE, Lee DH, Yoo C, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2011. 35:183–187.

18. Kang BW, Kim WS, Kim C, et al. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest New Drugs. 2010. 28:516–522.

19. Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008. 87:43–48.

20. Cheson BD, Horning SJ, Coiffier B, et al. NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999. 17:1244.

21. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003. 101:391–398.

22. Krishnan A, Palmer JM, Tsai NC, et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant. 2011. 18:441–450.

23. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol. 2005. 16:786–792.

24. Weigert O, Illidge T, Hiddemann W, Dreyling M. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer. 2006. 107:686–695.

25. Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2004. 19:478–481.

26. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007. 110:54–58.

27. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000. 95:1588–1593.

28. Seshadri T, Pintilie M, Tsang R, et al. Second cancers after autologous hematopoietic stem cell transplantation (ASCT) for relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). Blood. 2007. 110:Abst 1673.

29. Voso MT, Martin S, Hohaus S, et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 2000. 25:957–964.

30. de Kreuk M, Ossenkoppele GJ, Meijer CJ, Huijgens PC. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant. 1996. 17:963–971.